HK1111902A1 - Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof - Google Patents

Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof

Info

Publication number
HK1111902A1
HK1111902A1 HK08106750.9A HK08106750A HK1111902A1 HK 1111902 A1 HK1111902 A1 HK 1111902A1 HK 08106750 A HK08106750 A HK 08106750A HK 1111902 A1 HK1111902 A1 HK 1111902A1
Authority
HK
Hong Kong
Prior art keywords
diabetes
medicine
preparation
oral administration
controlled release
Prior art date
Application number
HK08106750.9A
Other languages
English (en)
Inventor
Jong Soo Woo
Hong Gi Yi
Moon Hyuk Chi
Young Hun Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of HK1111902A1 publication Critical patent/HK1111902A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
HK08106750.9A 2004-12-31 2008-06-18 Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof HK1111902A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020040117781A KR100760430B1 (ko) 2004-12-31 2004-12-31 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
PCT/KR2005/004609 WO2006071078A1 (en) 2004-12-31 2005-12-28 Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof

Publications (1)

Publication Number Publication Date
HK1111902A1 true HK1111902A1 (en) 2008-08-22

Family

ID=36615157

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08106750.9A HK1111902A1 (en) 2004-12-31 2008-06-18 Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof

Country Status (14)

Country Link
US (1) US20100003289A1 (es)
EP (1) EP1830820A4 (es)
JP (1) JP2008526733A (es)
KR (1) KR100760430B1 (es)
CN (1) CN101094657B (es)
AU (1) AU2005320362B2 (es)
BR (1) BRPI0519471A2 (es)
CA (1) CA2592173C (es)
HK (1) HK1111902A1 (es)
IL (1) IL183982A (es)
MX (1) MX2007008033A (es)
NZ (1) NZ556775A (es)
RU (1) RU2355386C2 (es)
WO (1) WO2006071078A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7501426B2 (en) 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
CN101801351B (zh) * 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
KR101512386B1 (ko) * 2008-04-08 2015-04-17 제이더블유중외제약 주식회사 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
EP2228066A1 (en) 2009-03-03 2010-09-15 LEK Pharmaceuticals d.d. Pharmaceutical compositions of sulphonylurea-based active pharmaceutical ingredient with excellent dissolution properties
US20120135952A1 (en) * 2009-07-17 2012-05-31 Hanall Biopharma Co., Ltd. Butyric acid salt of n,n-dimethyl imidocarbon imidic diamide, method of preparing same, and pharmaceutical compositions and combinations containing same
WO2011008053A2 (ko) * 2009-07-17 2011-01-20 한올바이오파마주식회사 Ｎ,ｎ-디메틸 이미도디카르본이미딕 디아미드의 프로피온산염, 이의 제조방법, 이를 포함하는 약제학적 조성물 및 이를 포함하는 복합제제
PT2482812T (pt) * 2009-10-02 2023-01-24 Boehringer Ingelheim Int Composições farmacêuticas compreendendo bi-1356 e metformina
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
KR101193495B1 (ko) 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
KR102240429B1 (ko) 2013-05-06 2021-04-15 한미약품 주식회사 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
KR101526825B1 (ko) * 2014-12-23 2015-06-08 주식회사 한독 당뇨병 치료용 약제학적 조성물
CN105878256B (zh) * 2015-01-05 2019-10-22 合肥立方制药股份有限公司 含有盐酸二甲双胍和格列美脲的控释制剂及其制备方法
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ
WO2018193572A1 (ja) * 2017-04-20 2018-10-25 株式会社島津製作所 分光光度計
KR102598700B1 (ko) * 2022-11-18 2023-11-07 고덕상 미네랄 촉매제를 이용한 그릇 제조방법
KR102598696B1 (ko) * 2022-11-18 2023-11-06 고덕상 미네랄 촉매제를 이용한 건축자재 제조방법
KR102598693B1 (ko) * 2022-11-18 2023-11-06 고덕상 미네랄 촉매제를 이용한 생활용품 제조방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3320583A1 (de) * 1983-06-08 1984-12-13 Dr. Karl Thomae Gmbh, 7950 Biberach Neue galenische zubereitungsformen von oralen antidiabetika und verfahren zu ihrer herstellung
SE9403158D0 (sv) * 1994-09-21 1994-09-21 Pharmacia Ab New use of prostaglandins
PT998271E (pt) * 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
EP2332522A3 (en) 1998-03-19 2011-12-07 Bristol-Myers Squibb Company Biphasic controlled release delivery system for high solubility pharmaceuticals and method
SI0974356T1 (en) * 1998-07-15 2003-12-31 Merck Sante Tablets comprising a combination of metformin and glibenclamide
MXPA02007254A (es) * 2000-02-04 2002-12-09 Depomed Inc Forma de dosis de cubierta-y-nucleo que se aproxima a liberacion de droga de orden cero.
ATE444060T1 (de) * 2001-06-22 2009-10-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren
US20040202718A1 (en) * 2001-09-28 2004-10-14 Tyebji Ziauddin Z. Dosage form for treatment of diabetes mellitus
US6682759B2 (en) 2002-02-01 2004-01-27 Depomed, Inc. Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
EP1562607A1 (en) * 2002-11-15 2005-08-17 Ranbaxy Laboratories, Ltd. Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
US20050163842A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Rosiglitazone and metformin formulations

Also Published As

Publication number Publication date
CN101094657A (zh) 2007-12-26
JP2008526733A (ja) 2008-07-24
RU2007129155A (ru) 2009-02-10
IL183982A0 (en) 2007-10-31
EP1830820A4 (en) 2012-10-24
AU2005320362B2 (en) 2009-02-26
WO2006071078A1 (en) 2006-07-06
US20100003289A1 (en) 2010-01-07
EP1830820A1 (en) 2007-09-12
CA2592173C (en) 2011-08-02
RU2355386C2 (ru) 2009-05-20
KR20060077812A (ko) 2006-07-05
AU2005320362A1 (en) 2006-07-06
CN101094657B (zh) 2012-01-04
NZ556775A (en) 2009-08-28
KR100760430B1 (ko) 2007-10-04
MX2007008033A (es) 2007-08-22
IL183982A (en) 2013-07-31
CA2592173A1 (en) 2006-07-06
BRPI0519471A2 (pt) 2009-01-27

Similar Documents

Publication Publication Date Title
HK1111902A1 (en) Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof
HK1192444A1 (zh) 注射裝置及混合藥物和用藥的方法
IL176519A0 (en) Directly compressible pharmaceutical composition for the oral administration of cci-779
EP1753380A4 (en) TRANSPARENT FORMULATIONS FOR THE DERIVATIVE DISPOSAL OF MEDICAMENTS AND METHODS OF ADMINISTRATION
GB2402063B (en) Pharmaceutical composition for controlled release of active substances and the manufacturing method thereof
IL221770A (en) Edamantyl acetamide derivatives, the pharmaceutical composition containing them and its use in the preparation of a drug
AP2006003788A0 (en) Traditional chines medicine preparation for cardiocerebral blood vessel diseases and its preparing method
IL178822A (en) Amide @@ - @Phenylamino-Quinzoline-6-YL, medicinal preparations containing them, and their use in the preparation of drugs for the treatment of proliferative disorders
EP1848541A4 (en) METHOD AND DEVICE FOR OPHTHALMIC DELIVERY OF PHARMACEUTICALLY ACTIVE INGREDIENTS
IL195931A0 (en) Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and methods for its production
IL198314A (en) History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment
PL1750700T3 (pl) Ciekły preparat dla medycyny weterynaryjnej; sposób jego wytwarzania i zastosowanie
EP1849448A4 (en) SYRINGE DEVICE AND METHOD FOR PREPARING A MEDICAMENT USING THE DEVICE
EP1722821A4 (en) COMPOSITION FOR THE ORAL ADMINISTRATION OF TAMSULOSIN HYDROCHLORIDE AND CONTROLLED RELEASE PELLETING FORMULATION COMPRISING THE SAME
IL188643A (en) Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production.
WO2006108692A3 (en) Dosage form for oral administration of a vitamin
WO2008113901A3 (fr) Composition à libération prolongée de lévétiracetam et procédé de préparation.
HK1142823A1 (en) Formulations for the oral administration of therapeutic agents and related methods
EP1753405A4 (en) SLOW RELEASE PHARMACEUTICAL PREPARATION
PL1753398T3 (pl) Macierz o kontrolowanym uwalnianiu farmaceutycznej formulacji dawkowania
EP1755568A4 (en) FORMULATION WITH CONTROLLED RELEASE FOR ORAL ADMINISTRATION OF METFORMIN
HK1100352A1 (en) Solid medicament of oral administration and preparation thereof
EP2196463A4 (en) PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, DERIVATIVES DERIVATED THEREOF AND PHARMACEUTICAL FORMULATIONS THEREOF
ZA200500556B (en) The pharmaceutical formulation of traditional chinese medicine for abstinence of drug and preparation method and use thereof
IL174081A0 (en) Formulation for obtaining a pharmaceutical composition, methods of obtaining and use thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20171228